Predictors of variation in serum IGFI and IGFBP3 levels in Healthy African American and White Men

Journal of the National Medical Association

Volumn 101, Issue 7, 2009, Pages 711-716

  Hoyo, Cathrine ^a,b   Grubber, Janet ^b   Demark Wahnefried, Wendy ^a   Lobaugh, Bruce ^a   Jeffreys, Amy S ^c   Grambow, Steven C ^a,c   Marks, Jeffrey R ^a   Keku, Ternitope O ^d   Walther, Phillip J ^a   Schildkraut, Joellen M ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Insulin; Race ethnicity

Indexed keywords

GENOMIC DNA; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; CAUCASIAN; CHRONIC DISEASE; CIGARETTE SMOKING; COLON CANCER; ETHNIC GROUP; FAMILY HISTORY; GENOTYPE; HUMAN; INTERVIEW; LIFESTYLE; MALE; MEN'S HEALTH; MULTIPLE LINEAR REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RISK FACTOR; SERUM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 68349085524     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30981-0     Document Type: Article

References (47)

1. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control. 1996;7:605-625.
2. Kaaks R. The epidemiology of diet and colorectal cancer: review and perspectives for future research using biological markers. Annali dell'Istituto superiore di sanita. 1996;32:111-121. (Pubitemid 126532096)
3. Vaessen N, Heutink P, Janssen JA, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes. 2001;50(3):637-642. (Pubitemid 32195230)
4. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90(17):1292-1299. (Pubitemid 28433474)
5. Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1566-1573. (Pubitemid 36020008)
6. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 20 2000;92(18):1472-1489. (Pubitemid 30757421)
7. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91(7):620-625. (Pubitemid 29194048)
8. Manousos O, Souglakos J, Bosetti C, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer. 1999;83(1):15-17. (Pubitemid 29409470)
9. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002;94(14):1099-1106. (Pubitemid 34830730)
10. Chokkalingam AP, Pollak M, Fillmore CM, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 2001;10(5):421-427. (Pubitemid 32701626)
11. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab. 2000;85(11):4258-4265.
12. Leitzmann MF. Is there a link between macronutrient intake and prostate cancer? Nat Clin Pract Oncol. 2005;2(4):184-185.
13. Li L, Yu H, Schumacher F, Casey G, Witte JS. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control. 2003;14(8):721-726. (Pubitemid 37463885)
14. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer. 1997;76(9):1115-1118. (Pubitemid 27448004)
15. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control. 2005;16(3):255-262.
16. Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer. 2001;85(7):991-996. (Pubitemid 33016002)
17. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000;92(23):1910-1917. (Pubitemid 32036921)
18. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst. 1998;90(12):911-915. (Pubitemid 28304159)
19. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3-34.
20. Ali O, Cohen P, Lee KW. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res. 2003;35(11-12):726-733. (Pubitemid 38058176)
21. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer. 2005;103(1):76-84. (Pubitemid 39665459)
22. Lopez J.B. RMS, L.P. Chin. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer? Int J Biol Markers. 2004;19:164-167.
23. Shariat SF, Lamb DJ, Kattan MW, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002;20(3):833-841.
24. Chang S, Wu X, Yu H, Spitz MR. Plasma concentrations of insulin-like growth factors among health adult men and postmenopausal women: Associations with body composition, lifestyle and reproductive factors. Cancer Epidemiol Biomarkers Prev. 2002;11:768-1766 (Pubitemid 34851911)
25. Gapstur SM, Kopp P, Chiu BC, Gann PH, Colangelo LA, Liu K. Longitudinal associations of age, anthropometric and lifestyle factors with serum total insulin-like growth factor-I and IGF binding protein-3 levels in Black and White men: the CARDIA Male Hormone Study. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2208-2216. (Pubitemid 40054319)
26. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol. 1997;145(11):970-976. (Pubitemid 27215479)
27. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomarkers Prev. 2005;14(6):1394-1401. (Pubitemid 40807337)
28. Barrett-Connor E, Goodman-Gruen D. Gender differences in insulin-like growth factor and bone mineral density association in old age: the Rancho Bernardo Study. J Bone Miner Res. 1998;13(8):1343-1349. (Pubitemid 28373337)
29. Kaklamani VG, Linos A, Kaklamani E, Markaki I, Mantzoros C. Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. J Clin Oncol. 1999;17(3):813-817. (Pubitemid 29109310)
30. DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, Le Marchand L. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2004;13(9):1444-1451. (Pubitemid 39202310)
31. Jernstrom H, Deal C, Wilkin F, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 2001;10(4):377-384. (Pubitemid 32703223)
32. Probst-Hensch NM, Wang H, Goh VH, Seow A, Lee HP, Yu MC. Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women. Cancer Epidemiol Biomarkers Prev. 2003;12(8):739-746. (Pubitemid 36993164)
33. Wright N.M. NP, S. Willi, et al. Demonstration of a lack of racial difference in secretion of growth hormone despite a racial difference in bone mineral density in premenopausal women - a Clinical Research Center study. J Clin. Endocrinol. Metab. 1996;81:1023-1026.
34. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab. 2001;86(3):1274- 1280. (Pubitemid 32323016)
35. Rietveld I, Janssen JA, van Rossum EF, et al. A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. Clin Endocrinol (Oxf). 2004;61(2):195-203. (Pubitemid 39093114)
36. Rosen CJ, Kurland ES, Vereault D, et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab. 1998;83(7):2286-2290. (Pubitemid 28503015)
37. Schildkraut JM, Demark-Wahnefried W, Wenham RM, et al. IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev. 2005;14(2):403-408. (Pubitemid 40270104)
38. Hoyo C, Grubber J, Demark-Wahnefried W, et al. Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. J Natl Med Assoc. 2007;99(7):718-722. (Pubitemid 47076139)
39. Cheng I, DeLellis Henderson K, Haiman CA, et al. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab. 2007;92(9):3660-3666. (Pubitemid 47435353)
40. McGreevy KM, Hoel BD, Lipsitz SR, Hoel DG. Impact of nutrients on insulin-like growth factor-I, insulin-like growth factor binding protein-3 and their ratio in African American and white males. Public Health Nutr. 2007;10(1):97-105.
41. Maskarinec G, Takata Y, Murphy SP, Franke AA, Kaaks R. Insulin-like growth factor-1 and binding protein-3 in a 2-year soya intervention among premenopausal women. Br J Nutr. 2005;94(3):362-367. (Pubitemid 41404278)
42. Allen NE, Appleby PN, Kaaks R, Rinaldi S, Davey GK, Key TJ. Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Control. 2003;14(1):65-74. (Pubitemid 36403271)
43. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf). 1994;41(3):351-357. (Pubitemid 24278330)
44. Teramukai S, Rohan T, Lee KY, Eguchi H, Oda T, Kono S. Insulin-like growth factor (IGF)-I, IGF-binding protein-3 and colorectal adenomas in Japanese men. Jpn J Cancer Res. 2002;93(11):1187-1194. (Pubitemid 36032980)
45. Lukanova A, Toniolo P, Akhmedkhanov A, et al. A cross-sectional study of IGF-I determinants in women. Eur J Cancer Prev. 2001;10(5):443-452. (Pubitemid 33016255)
46. Signorello LB, Adami HO. Prostate Cancer. In: Adami H-O HD, Trichopoulos D, ed. Textbook of Cancer Epidemiology. Vol 1. New York: Oxford University Press; 2002:599.
47. Akanji AO, Suresh CG, Al-Radwan R, Fatania HR. Insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein (IGFBP)-3 levels in Arab subjects with coronary heart disease. Scand J Clin Lab Invest. 2007;67(5):553-559. (Pubitemid 47344351)